How is NuTec different from other clinical tests?
NuTEC is envisioned as a single device diagnosing many diseases as opposed to many individual tests in the hospital each diagnosing a single disease.
How do NuTec signatures work differently from individual tests?
The two are not mutually exclusive. Signatures allow you to ask the open-ended and unbiased question: ‘Is there a problem?’ However, if you have a specific question such as ‘Do I have diabetes mellitus?’ a specific test for glucose levels would make more sense.
Does NuTec detect DNA, RNA, proteins or small molecules?
NuTec is unbiased and reacts with all 4 classes. The resulting spots on the NuTec are not DNA, RNA, proteins and small molecules but rather the colorimetric products of these chemical reactions.
How is the NuTec signature generated?
A mixture of molecules in a sample applied to the NuTec undergoes chemical reactions upon heating which then result in a visual pattern of dark and light spots. By design, each spot on the NuTec reacts differently with the sample molecules. Physicochemical diversity among the spots is important for NuTec to search through a large enough chemical space in the sample. This diversity is the basis for generating the spot pattern.
What is the NuTec signature?
The NuTec signature is analogous to a hash function. A hash function takes information of arbitrary length (e.g. a large image file) and generates an output signature with a drastically smaller length (e.g. a string of 32 characters). The NuTec is the chemical version of a hash function. Just like a hash function, NuTec takes dimensionally large chemical information in a sample and reduces it to a chemical hash of X defined spots. Hash signatures are a great way of telling if a file downloaded off the internet matches the original. In the same way, Entopsis will be matching your chemical hash signature to a database of pre-validated hashes.
Are there other current approaches using signatures and how is NuTec different?
What sets NuTec apart from other platforms is the chemical hash concept. Chemical hashing does several things. It transforms chemical information into colorimetric information which can be acquired by a scanner or phone camera. It lets NuTec survey a chemical space which is unimaginably complex. The resulting hash signature is compact and easily amenable to database storage and template matching.
Is Entopsis ISO certified?
Yes, Dr. Tingjun Lei and the Entopsis manufacturing team have achieved ISO 9001:2015 and ISO 13485:2016 certification for the manufacture and sale of NuTec devices.
Non-invasive OpsisDx Diagnostic Test Awarded US Academy of Medicine Research Global Award
The U.S. National Academy of Medicine’s Healthy Longevity Global Grand Challenge has awarded a grant to develop Entopsis’ OpsisDx(TM) platform for detecting Parkinson’s disease using skin swabs or urine. This effort is driven by Entopsis’ scientific and clinical collaborators at Singapore’s Temasek Life Sciences Laboratory (TLL) and National Neuroscience Institute (NNI).
Read more about it here:
Non-invasive OpsisDx Diagnostic Test Awarded US Academy Research Grant
Entopsis Partners with Madison Core Labs: PCRopsis Reagent RVD
Our team’s passion is to innovate and create powerful, unheard-of solutions to the world’s problems. We pride ourselves on our creativity and desire to make a meaningful difference, both socially and scientifically.
However, we can only achieve our global goals with the right partners that share our mission. Today’s press release (see below) highlights one such partner, Madison Core Labs.
Madison Core Laboratories Initiates New Innovation Effort to Better Serve Clients
August 13, 2020 09:05 AM Eastern Daylight Time
HUNTSVILLE, Ala.–(BUSINESS WIRE)–
GIA Expands Commercialization of OpsisDx Tests
Genetics Institute of America (GIA) received IRB approval to expand its Prostate Cancer Study (GH215) utilizing OpsisDx to include: Breast, Ovarian and Lung Cancers. OpsisDx will be used to develop accurate, non-invasive tests for the early detection of these 3 additional cancers.
GIA, empowered by OpsisDx, will be able to screen people for prostate, breast, ovarian, and / or lung cancers once these 4 studies are completed. These tests are expected to detect tumors earlier than liquid biopsies and thereby outperform GRAIL (valued at over $4 billion).
The Entopsis team will continue to support GIA’s efforts of bring impactful tools
